β-cell function after weight-Loss induced by Bariatric surgery

Physiology

Volumn 29, Issue 2, 2014, Pages 84-85

  Vella, Adrian ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BARIATRIC SURGERY; CYTOLOGY; HUMAN; OBESITY; PANCREAS ISLET BETA CELL; WEIGHT REDUCTION;

BARIATRIC SURGERY; HUMANS; INSULIN-SECRETING CELLS; OBESITY; WEIGHT LOSS;

EID: 84900800836     PISSN: 15489213     EISSN: 15489221     Source Type: Journal    
DOI: 10.1152/physiol.00003.2014     Document Type: Article

References (28)

1. Basu A, Alzaid A, Dinneen S, Caumo A, Cobelli C, Rizza RA. Effects of a change in the pattern of insulin delivery on carbohydrate tolerance in diabetic and nondiabetic humans in the presence of differing degrees of insulin resistance. J Clin Invest 97: 2351-2361, 1996.
2. Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrbach K, Schoelles K. Bariatric surgery: a systematic review and meta-analysis. JAMA 292: 1724-1737, 2004.
3. Buse JB, Caprio S, Cefalu WT, Ceriello A, Del Prato S, Inzucchi SE, McLaughlin S, Phillips GL, 2nd Robertson RP, Rubino F, Kahn R, Kirkman MS. How do we define cure of diabetes? Diabetes Care 32: 2133-2135, 2009.
4. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52: 102-110, 2003.
5. Campioni M, Toffolo G, Shuster LT, Service FJ, Rizza RA, Cobelli C. Incretin effect potentiates beta-cell responsivity to glucose as well as to its rate of change: OGTT and matched intravenous study. Am J Physiol Endocrinol Metab 292: E54-E60, 2007.
6. Cobelli C, Dalla Man C, Sparacino G, Magni L, De Nicolao G, Kovatchev BP. Diabetes: models, signals, control. IEEE Rev Biomed Eng 2: 54-96, 2009.
7. Cummings DE. Gastric bypass and nesidioblasto-sis: too much of a good thing for islets? N Engl J Med 353: 300-302, 2005.
8. Dirksen C, Bojsen-Moller KN, Jorgensen NB, Jacob-sen SH, Kristiansen VB, Naver LS, Hansen DL, Worm D, Holst JJ, Madsbad S. Exaggerated release and preserved insulinotropic action of glucagon-like pep-tide-1 underlie insulin hypersecretion in glucose-tolerant individuals after Roux-en-Y gastric bypass. Diabetologia 56: 2679-2687, 2013.
9. Ikramuddin S, Korner J, Lee WJ, Connett JE, Inabnet WB, Billington CJ, Thomas AJ, Leslie DB, Chong K, Jeffery RW, Ahmed L, Vella A, Chuang LM, Bessler M, Sarr MG, Swain JM, Laqua P, Jensen MD, Bantle JP. Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipid-emia: the Diabetes Surgery Study randomized clinical trial. JAMA 309: 2240-2249, 2013.
10. Jackness C, karmally W, Febres G, Conwell IM, Ahmed L, Bessler M, McMahon DJ, Korner J. Very low calorie diet mimics the early beneficial effect of Roux-en-Y gastric bypass on insulin sensitivity and beta-cell function in type 2 diabetic patients. Diabetes 62: 3027-3032, 2013.
11. Jimenez A, Casamitjana R, Viaplana-Masclans J, Lacy A, Vidal J. GLP-1 action and glucose tolerance in subjects with remission of type 2 diabetes after gastric bypass surgery. Diabetes Care 36: 2062-2069, 2013.
12. Jorgensen NB, Dirksen C, Bojsen-Moller KN, Jacob-sen SH, Worm D, Hansen DL, Kristiansen VB, Naver L, Madsbad S, Holst JJ. Exaggerated glucagon-like peptide-1 response is important for the improved beta-cell function and glucose tolerance after Roux-en-Y gastric bypass in patients with type 2 diabetes. Diabetes 62: 3044-3052, 2013.
13. Kelley DE, Wing R, Buonocore C, Sturis J, Polon-sky K, Fitzsimmons M. Relative effects of calorie restriction and weight loss in noninsulin-depen-dent diabetes mellitus. J Clin Endocrinol Metab 77: 1287-1293, 1993.
14. Koebnick C, Smith N, Huang K, Martinez MP, Clancy HA, Kushi LH. The prevalence of obesity and obesity-related health conditions in a large, multiethnic cohort of young adults in California. Ann Epidemiol 22: 609-616, 2012.
15. Laferrere B, Teixeira J, McGinty J, Tran H, Egger JR, Colarusso A, Kovack B, Bawa B, Koshy N, Lee H, Yapp K, Olivan B. Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. J Clin Endocrinol Metab 93: 2479-2485, 2008.
16. Leahy JL. Natural history of beta-cell dysfunction in NIDDM. Diabetes Care 13: 992-1010, 1990.
17. Matveyenko AV, Veldhuis JD, Butler PC. Adaptations in pulsatile insulin secretion, hepatic insulin clearance, and beta-cell mass to age-related insulin resistance in rats. Am J Physiol Endocrinol Metab 295: E832-E841, 2008.
18. Meier JJ, Butler AE, Galasso R, Butler PC. Hyper-insulinemic hypoglycemia after gastric bypass surgery is not accompanied by islet hyperplasia or increased beta-cell turnover. Diabetes Care 29: 1554-1559, 2006.
19. Mingrone G, Panunzi S, De Gaetano A, Guidone C, Iaconelli A, Leccesi L, Nanni G, Pomp A, Castagneto M, Ghirlanda G, Rubino F. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med 366: 1577-1585, 2012.
20. Porksen N, Hollingdal M, Juhl C, Butler P, Veld-huis JD, Schmitz O. Pulsatile insulin secretion: detection, regulation, and role in diabetes. Diabetes 51, Suppl 1: S245-S254, 2002.
21. Sathananthan A, Man CD, Zinsmeister AR, Camil-leri M, Rodeheffer RJ, Toffolo G, Cobelli C, Rizza RA, Vella A. A concerted decline in insulin secretion and action occurs across the spectrum of fasting and postchallenge glucose concentrations. Clin Endocrinol (Oxf) 76: 212-219, 2012.
22. Schauer PR, Kashyap SR, Wolski K, Brethauer SA, Kirwan JP, Pothier CE, Thomas S, Abood B, Nis-sen SE, Bhatt DL. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med 366: 1567-1576, 2012.
23. Service GJ, Thompson GB, Service FJ, Andrews JC, Collazo-Clavell ML, Lloyd RV. Hyperinsuline-mic hypoglycemia with nesidioblastosis after gastric-bypass surgery. N Engl J Med 353: 249-254, 2005.
24. Shah M, Law JH, Micheletto F, Sathananthan M, Dalla Man C, Cobelli C, Rizza RA, Camilleri M, Zinsmeister AR, Vella A. The contribution of endogenous glucagon-like peptide-1 to glucose metabolism after Roux-en-Y gastric bypass. Diabetes. In press.
25. Shah P, Vella A, Basu A, Basu R, Schwenk WF, Rizza RA. Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 85: 4053-4059, 2000.
26. Still CD, Wood GC, Benotti P, Petrick AT, Gabri-elsen J, Strodel WE, Ibele A, Seiler J, Irving BA, Celaya MP, Blackstone R, Gerhard GS, Argyro-poulos G. Preoperative prediction of type 2 diabetes remission after Roux-en-Y gastric bypass surgery: a retrospective cohort study. Lancet Diab Endocrinol 2: 38-45, 2014.
27. Vella A, Service FJ. Incretin hypersecretion in post-gastric bypass hypoglycemia primary problem or red herring? J Clin Endocrinol Metab 92: 4563-4565, 2007.
28. Wickremesekera K, Miller G, Naotunne TD, Knowles G, Stubbs RS. Loss of insulin resistance after Roux-en-Y gastric bypass surgery: a time course study. Obes Surg 15: 474-481, 2005.